SAN DIEGO, March 13, 2019 /PRNewswire/ -- Biocept, Inc.
(NASDAQ: BIOC), a leading commercial provider of liquid biopsy
tests designed to provide physicians with clinically actionable
information to improve the outcomes of patients diagnosed with
cancer, announces that it has expanded its pathology partnership
platform, EmpowerTCTM, to now offer local pathologists
the ability to analyze prognostic and predictive markers on CTCs
from a liquid biopsy using immunocytochemistry (ICC) methods. This
new offering, in addition to an expanded biomarker menu,
supplements the previous capabilities of Biocept's proprietary
pathology partnership platform to analyze liquid biopsy biomarkers
using fluorescence in situ hybridization (FISH) methods.
"Unlike other liquid biopsy services, Biocept's pathology
partnership service enables me to incorporate cutting-edge liquid
biopsy technology into my practice so I can remain closely
connected to the laboratory results supporting the care of our
patients with cancer," said Anthony M.
Magliocco, MD, FRCPC, FCAP, Co-founder and President of
Protean BioDiagnostics, Inc. "I am looking forward to
evaluating the Company's expanded service capabilities to
potentially yield more information about our patients' disease, and
the ability to personalize treatment based on the dynamic biomarker
information that can be obtained from a liquid biopsy."
"We are extremely pleased to begin offering our enhanced
EmpowerTC v2.0 service to our customers, as these new tools and
technologies are designed to enable local pathologists access to
liquid biopsy and the ability to remain in the continuum of care
with their patients," said Edwin
Hendrick, Chief Commercial Officer of
Biocept. "We believe that our pathology partnership
platform distinguishes Biocept from other liquid biopsy services,
and we plan to continue to innovate and launch additional markers
to expand this service further in the future."
About Biocept's Pathology Partnership Offering
Biocept's EmpowerTC offering provides liquid biopsy services to
pathologists, thereby extending our partners' breadth of laboratory
offerings. This offering empowers pathologists to combine their
skills, knowledge and experience with Biocept's patented and
proprietary liquid biopsy platform technology. For more information
about Biocept's EmpowerTC testing service, please contact Biocept
Customer Services at 888.332.7729.
About Biocept
Biocept, Inc. is a molecular diagnostics company with
commercialized assays for lung, breast, gastric, colorectal and
prostate cancers, and melanoma. The Company uses its
proprietary liquid biopsy technology to provide physicians with
information for treating and monitoring patients diagnosed with
cancer. The Company's patented Target Selector™ liquid biopsy
technology platform captures and analyzes tumor-associated
molecular markers in both CTCs and in plasma (ctDNA). With
thousands of tests performed, the platform has demonstrated the
ability to identify cancer mutations and alterations to inform
physicians about a patient's disease and therapeutic options. For
additional information, please visit www.biocept.com.
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based
upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance that such expectations and assumptions will prove to
have been correct. Forward-looking statements are generally
identifiable by the use of words like "may," "will," "should,"
"could," "expect," "anticipate," "estimate," "believe," "intend,"
or "project" or the negative of these words or other variations on
these words or comparable terminology. To the extent that
statements in this release are not strictly historical, including
without limitation statements as to our ability to improve the
outcomes of patients diagnosed with cancer, the potential clinical
utility of our proprietary technology platform and our ability
to innovate and launch additional markers to expand our
EmpowerTC offering , such statements are forward-looking, and are
made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. The reader is cautioned
not to put undue reliance on these forward-looking statements, as
these statements are subject to numerous risk factors as set forth
in our Securities and Exchange Commission (SEC) filings. The
effects of such risks and uncertainties could cause actual results
to differ materially from the forward-looking statements contained
in this release. We do not plan to update any such forward-looking
statements and expressly disclaim any duty to update the
information contained in this press release except as required by
law. Readers are advised to review our filings with the SEC, which
can be accessed over the Internet at the SEC's website located at
www.sec.gov.
Contact:
LHA Investor Relations
Jody Cain
Jcain@lhai.com
310-691-7100
View original content to download
multimedia:http://www.prnewswire.com/news-releases/biocept-expands-its-pathology-partnership-offering-for-liquid-biopsy-with-the-addition-of-several-key-services-300808968.html
SOURCE Biocept, Inc.